
Leading XPRIZE Healthspan and Beating Negativity, with Dr. Peter Diamandis
12/06/23 • 60 min
A new competition by the XPRIZE Foundation is offering $101 million to researchers if they discover therapies that allow seniors to perform like when they were 10 to 20 years younger.
For today’s episode, I talked with Dr. Peter Diamandis, XPRIZE’s founder and executive chairman. Under Peter’s leadership, XPRIZE has launched 27 previous competitions with over $300 million in prize purses.
The lastest contest aims to enhance healthspan, or the period of life when older people can play with their grandkids without any restriction, disability or disease. The biggest prize for this competition, called XPRIZE Healthspan, is $81 million for improvements that restore cognition, muscle and immunity by two decades. Sponsors include Hevolution Foundation, a nonprofit, and Chip Wilson, the founder of Lululemon and the nonprofit SOLVE FSHD.
In our conversation, Peter explains why exponential technologies make the current era the most exciting time in human history. We discuss the best mental outlook for becoming truly innovative; how to overcome the negativity bias in ourselves and in mainstream media; how Peter has shifted his own mindset to become more positive; his personal recommendations for healthy lifestyle; the future of education; and the importance of democratizing tech and innovation, among many other topics.
In addition to Peter’s role with XPRIZE, he's the Executive Founder of Singularity University. In 2014, Fortune named him one of the “World’s 50 Greatest Leaders.” He has started over 25 companies in health-tech, space, venture capital and education. Peter is the author of multiple New York Times bestselling books, linked below, and holds degrees in molecular genetics and aerospace engineering from MIT, as well as an M.D. from Harvard University.
Show links
New XPRIZE Healthspan
Peter Diamandis bio
27 XPRIZE competitions and counting
Peter Diamandis books
Life Force by Peter Diamandis and Tony Robbins
Peter Diamandis Twitter
Longevity Insider newsletter – AI identifies the news
Peter Diamandis Longevity Handbook
Making Sense of Science features interviews with leading medical and scientific experts about the latest developments in health innovation and the big ethical and social questions they raise. The podcast is hosted by science journalist Matt Fuchs
A new competition by the XPRIZE Foundation is offering $101 million to researchers if they discover therapies that allow seniors to perform like when they were 10 to 20 years younger.
For today’s episode, I talked with Dr. Peter Diamandis, XPRIZE’s founder and executive chairman. Under Peter’s leadership, XPRIZE has launched 27 previous competitions with over $300 million in prize purses.
The lastest contest aims to enhance healthspan, or the period of life when older people can play with their grandkids without any restriction, disability or disease. The biggest prize for this competition, called XPRIZE Healthspan, is $81 million for improvements that restore cognition, muscle and immunity by two decades. Sponsors include Hevolution Foundation, a nonprofit, and Chip Wilson, the founder of Lululemon and the nonprofit SOLVE FSHD.
In our conversation, Peter explains why exponential technologies make the current era the most exciting time in human history. We discuss the best mental outlook for becoming truly innovative; how to overcome the negativity bias in ourselves and in mainstream media; how Peter has shifted his own mindset to become more positive; his personal recommendations for healthy lifestyle; the future of education; and the importance of democratizing tech and innovation, among many other topics.
In addition to Peter’s role with XPRIZE, he's the Executive Founder of Singularity University. In 2014, Fortune named him one of the “World’s 50 Greatest Leaders.” He has started over 25 companies in health-tech, space, venture capital and education. Peter is the author of multiple New York Times bestselling books, linked below, and holds degrees in molecular genetics and aerospace engineering from MIT, as well as an M.D. from Harvard University.
Show links
New XPRIZE Healthspan
Peter Diamandis bio
27 XPRIZE competitions and counting
Peter Diamandis books
Life Force by Peter Diamandis and Tony Robbins
Peter Diamandis Twitter
Longevity Insider newsletter – AI identifies the news
Peter Diamandis Longevity Handbook
Making Sense of Science features interviews with leading medical and scientific experts about the latest developments in health innovation and the big ethical and social questions they raise. The podcast is hosted by science journalist Matt Fuchs
Previous Episode

New psychedelics that rewire the brain for more well-being, with Doug Drysdale
A promising development in science in recent years has been the advance of technologies that take something natural and use technology to optimize it. This episode features a fascinating example: using tech to optimize psychedelic mushrooms.
These mushrooms have been used for religious, spiritual and medicinal purposes for thousands of years but only in the past several decades have scientists brought psychedelics into the lab to enhance them and maximize their therapeutic value.
Today’s podcast guest, Doug Drysdale, is doing important work to lead this effort. Drysdale is the CEO of a company called Cybin that has figured out how to make psilocybin more potent, so it can be administered in smaller doses without side effects.
Cybin isn’t Drysdale’s first go around at this. He has over 30 years of experience in the healthcare sector. During this time he’s raised around $4 billion of both public and private capital, and has been named Ernst and Young Entrepreneur of the Year. Before Cybin, he was the founding CEO of a pharmaceutical company called Alvogen, leading it from inception to around $500 million in revenues, across 35 countries. Drysdale has also been the head of mergers and acquisitions at Actavis Group, leading 15 corporate acquisitions across three continents.
In this episode, Drysdale walks us through the promising research of his current company, Cybin, and the different therapies he’s developing for anxiety and depression based not just on psilocybin but another psychedelic compound found in plants called DMT. He explains how they seem to have such powerful effects on the brain, as well as the potential for psychedelics to eventually support other use cases, including helping us strive toward higher levels of well-being. He goes on to discuss his views on mindfulness and lifestyle factors - such as optimal nutrition - that could help bring out the best in psychedelics.
Show links:
Doug Drysdale full bio
Doug Drysdale twitterCybin website
Cybin development pipeline
Cybin's promising phase 2 research on depression
Johns Hopkins psychedelics research and psilocybin research
Mets owner Steve Cohen invests in psychedelic therapies
Making Sense of Science features interviews with leading medical and scientific experts about the latest developments in health innovation and the big ethical and social questions they raise. The podcast is hosted by science journalist Matt Fuchs
Next Episode

How to Use the Immune System Against Cancer and Alzheimer's, with Dr. Paul Song
On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.
Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.
In the realm of cancer, Dr. Song is similarly setting his sights on another group of patients for whom treatment options are few and far between: people with solid tumors. Whereas some gradual progress has been made in treating blood cancers such as certain leukemias in past few decades, solid tumors have been even more of a challenge. But Dr. Song’s approach of using natural killer cells to treat solid tumors is promising. You may have heard of CAR-T, which uses genetic engineering to introduce cells into the body that have a particular function to help treat a disease. NKGen focuses on other means to enhance the 40 plus receptors of natural killer cells, making them more receptive and sensitive to picking out cancer cells.
Dr. Song is the grandson of the late Sang Don Kim, who was the first popularly elected Mayor of Seoul, South Korea. Dr. Song serves as the co-chair for a Campaign for a Healthy California. In 2013, he was named and served as the very first visiting fellow on healthcare policy in the California Department of Insurance. In addition, Dr. Song serves on the executive board of Physicians for a National Health Program California, People for the American Way, Progressive Democrats of America, Healthcare NOW, The Eisner Pediatric and Women's Center, and the Asian Pacific American Institute for Congressional Studies. Dr. Song graduated with honors from the University of Chicago, received his M.D. from George Washington University and completed his residency in radiation oncology at the University of Chicago. He sees Medicaid and uninsured patients at Dignity California Hospital.
With Dr. Song’s leadership, NKGen’s work on natural killer cells represents cutting-edge science that’s resulting in key findings about two of humanity’s most intractable diseases – contributing important pieces of the puzzle for treating them.
Making Sense of Science features interviews with leading medical and scientific experts about the latest developments in health innovation and the big ethical and social questions they raise. The podcast is hosted by science journalist Matt Fuchs
If you like this episode you’ll love
Episode Comments
Generate a badge
Get a badge for your website that links back to this episode
<a href="https://goodpods.com/podcasts/making-sense-of-science-238542/leading-xprize-healthspan-and-beating-negativity-with-dr-peter-diamand-38743994"> <img src="https://storage.googleapis.com/goodpods-images-bucket/badges/generic-badge-1.svg" alt="listen to leading xprize healthspan and beating negativity, with dr. peter diamandis on goodpods" style="width: 225px" /> </a>
Copy